Catalio Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Catalio Capital Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$709K	Hold	528,993	–	–	0.15%	38
2025 Q4	$857K	Hold	528,993	–	–	0.15%	42
2025 Q3	$1.25M	Hold	528,993	–	–	0.23%	32
2025 Q2	$783K	Hold	528,993	–	–	0.16%	34
2025 Q1	$719K	Hold	528,993	–	–	0.18%	30
2024 Q4	$1.91M	Buy	+528,993	New	+$1.28M	0.42%	27

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Catalio Capital Management's MGX Position: Q1 2026 in Review

Catalio Capital Management held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 528,993 shares worth $709K. The position accounts for 0.15% of the portfolio, ranked #38.

Catalio Capital Management first reported a position in MGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.91M in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Catalio Capital Management held 528,993 shares of Metagenomi Therapeutics worth $709K as of Q1 2026.
Catalio Capital Management left its Metagenomi Therapeutics share count unchanged in Q1 2026.
Metagenomi Therapeutics made up 0.15% of Catalio Capital Management's portfolio in Q1 2026, its #38 holding.
Catalio Capital Management first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 6 quarters since.
Catalio Capital Management's Metagenomi Therapeutics position peaked at $1.91M in Q4 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.